About REGENXBIO (NASDAQ:RGNX)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181
Debt
Debt-to-Equity RatioN/A
Current Ratio11.64%
Quick Ratio11.64%
Price-To-Earnings
Trailing P/E Ratio-15.20
Forward P/E Ratio-15.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$10.39 million
Price / Sales114.26
Cash FlowN/A
Price / CashN/A
Book Value$5.88 per share
Price / Book6.34
Profitability
EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins-704.02%
Return on Equity-36.48%
Return on Assets-34.17%
Miscellaneous
Employees139
Outstanding Shares31,870,000
REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions
What is REGENXBIO's stock symbol?
REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."
How were REGENXBIO's earnings last quarter?
REGENXBIO Inc. (NASDAQ:RGNX) issued its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.20. The biotechnology company had revenue of $2.04 million for the quarter. REGENXBIO had a negative net margin of 704.02% and a negative return on equity of 36.48%. View REGENXBIO's Earnings History.
When is REGENXBIO's next earnings date?
What price target have analysts set for RGNX?
7 Wall Street analysts have issued 1 year price targets for REGENXBIO's stock. Their forecasts range from $25.00 to $90.00. On average, they expect REGENXBIO's stock price to reach $42.7143 in the next year. View Analyst Ratings for REGENXBIO.
What are Wall Street analysts saying about REGENXBIO stock?
Here are some recent quotes from research analysts about REGENXBIO stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (4/17/2018)
- 2. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
Who are some of REGENXBIO's key competitors?
Some companies that are related to REGENXBIO include Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and DBV Technologies (DBVT).
Who are REGENXBIO's key executives?
REGENXBIO's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
- Mr. Vittal K. Vasista, CFO & Principal Accounting Officer (Age 50)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)
- Mr. Andrew Yost, VP of Corp. Devel.
Has REGENXBIO been receiving favorable news coverage?
News stories about RGNX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. REGENXBIO earned a news impact score of 0.22 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of REGENXBIO?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is REGENXBIO's stock price today?
One share of RGNX stock can currently be purchased for approximately $37.25.
How big of a company is REGENXBIO?
REGENXBIO has a market capitalization of $1.26 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. REGENXBIO employs 139 workers across the globe.
How can I contact REGENXBIO?
REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for REGENXBIO (RGNX)
MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
REGENXBIO (NASDAQ:RGNX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
REGENXBIO (NASDAQ RGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 67.63%
REGENXBIO (NASDAQ RGNX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Vittal Vasista | CFO | Sell | 5,000 | $37.56 | $187,800.00 | 154,434 |  |
| 4/11/2018 | Patrick J Christmas | SVP | Sell | 10,000 | $39.00 | $390,000.00 | 11,141 | |
| 4/9/2018 | Patrick J Christmas | SVP | Sell | 10,000 | $34.00 | $340,000.00 | 11,141 | |
| 3/26/2018 | Vittal Vasista | CFO | Sell | 5,000 | $30.00 | $150,000.00 | 157,283 | |
| 3/20/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $29.55 | $295,500.00 | 228,530 | |
| 3/13/2018 | Curran Simpson | SVP | Sell | 25,000 | $33.00 | $825,000.00 | | |
| 2/20/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $26.56 | $265,600.00 | 238,530 | |
| 1/22/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $27.33 | $273,300.00 | 248,530 | |
| 1/16/2018 | Vittal Vasista | CFO | Sell | 5,000 | $30.16 | $150,800.00 | | |
| 12/22/2017 | Curran Simpson | SVP | Sell | 30,000 | $33.03 | $990,900.00 | 69,500 | |
| 12/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $31.75 | $317,500.00 | 108,530 | |
| 12/19/2017 | Vittal Vasista | CFO | Sell | 5,000 | $30.00 | $150,000.00 | 87,277 | |
| 12/7/2017 | Curran Simpson | SVP | Sell | 21,890 | $30.04 | $657,575.60 | 41,390 | |
| 12/4/2017 | Curran Simpson | SVP | Sell | 110 | $30.00 | $3,300.00 | 39,610 | |
| 11/27/2017 | Curran Simpson | SVP | Sell | 2,000 | $29.31 | $58,620.00 | 41,500 | |
| 11/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $27.71 | $277,100.00 | | |
| 10/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $32.62 | $326,200.00 | 98,730 | |
| 10/16/2017 | Vittal Vasista | CFO | Sell | 5,000 | $33.25 | $166,250.00 | 92,283 | |
| 10/11/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $34.95 | $699,000.00 | | |
| 9/27/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $32.45 | $649,000.00 | 20,000 | |
| 9/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $29.33 | $293,300.00 | 108,630 | |
| 9/18/2017 | Donald J Hayden Jr | Director | Sell | 40,000 | $28.70 | $1,148,000.00 | 20,000 | |
| 9/15/2017 | Vittal Vasista | CFO | Sell | 5,000 | $27.39 | $136,950.00 | 99,594 | |
| 9/8/2017 | Stephen Yoo | Insider | Sell | 27,342 | $25.00 | $683,550.00 | 27,342 | |
| 9/6/2017 | Stephen Yoo | Insider | Sell | 32,658 | $25.00 | $816,450.00 | 31,803 | |
| 9/5/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $24.95 | $499,000.00 | 20,000 | |
| 9/5/2017 | Kenneth T Mills | Insider | Sell | 10,500 | $25.00 | $262,500.00 | 118,530 | |
| 8/21/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $20.05 | $130,325.00 | 105,500 | |
| 8/15/2017 | Vittal Vasista | CFO | Sell | 3,040 | $21.09 | $64,113.60 | 103,118 | |
| 7/20/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $18.66 | $121,290.00 | 112,000 | |
| 7/17/2017 | Vittal Vasista | CFO | Sell | 3,100 | $19.81 | $61,411.00 | 108,423 | |
| 6/20/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $19.68 | $127,920.00 | 119,396 | |
| 6/15/2017 | Vittal Vasista | CFO | Sell | 3,100 | $18.75 | $58,125.00 | 107,512 | |
| 4/24/2017 | Donald J Hayden Jr | Director | Sell | 10,000 | $20.98 | $209,800.00 | 28,599 | |
| 4/24/2017 | Kenneth T Mills | Insider | Sell | 15,440 | $20.98 | $323,931.20 | 126,395 | |
| 4/24/2017 | Vittal Vasista | CFO | Sell | 3,100 | $21.00 | $65,100.00 | 114,039 | |
| 5/17/2016 | Fmr Llc | Insider | Sell | 18,300 | $12.41 | $227,103.00 | | |
| 5/16/2016 | Fmr Llc | Insider | Sell | 16,030 | $11.65 | $186,749.50 | | |
| 5/12/2016 | Fmr Llc | Insider | Sell | 6,711 | $10.85 | $72,814.35 | | |
| 5/11/2016 | Fmr Llc | Insider | Sell | 25,132 | $10.36 | $260,367.52 | | |
| 5/9/2016 | Fmr Llc | Insider | Sell | 10,570 | $9.94 | $105,065.80 | | |
| 5/4/2016 | Fmr Llc | Insider | Sell | 1,896 | $10.51 | $19,926.96 | | |
| 5/3/2016 | Fmr Llc | Insider | Sell | 6,046 | $10.76 | $65,054.96 | | |
| 4/29/2016 | Fmr Llc | Insider | Sell | 4,723 | $10.80 | $51,008.40 | | |
| 4/28/2016 | Fmr Llc | Insider | Sell | 33,196 | $11.23 | $372,791.08 | | |
| 4/26/2016 | Fmr Llc | Insider | Sell | 9,188 | $11.19 | $102,813.72 | | |
| 4/22/2016 | Fmr Llc | Insider | Sell | 20,558 | $11.30 | $232,305.40 | | |
| 4/20/2016 | Fmr Llc | Insider | Sell | 13,189 | $11.66 | $153,783.74 | | |
| 4/18/2016 | Fmr Llc | Insider | Sell | 18,900 | $11.75 | $222,075.00 | | |
| 4/14/2016 | Fmr Llc | Insider | Sell | 27,036 | $11.46 | $309,832.56 | | |
| 9/22/2015 | James E Flynn | Insider | Buy | 175,000 | $22.00 | $3,850,000.00 | | |
(Data available from 1/1/2013 forward)
REGENXBIO (NASDAQ RGNX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | REGENXBIO Inc. (RGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 23 at 3:34 AM |
| REGENXBIO (RGNX) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM |
| Insider Selling: REGENXBIO Inc. (RGNX) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 18 at 7:46 PM |
 | Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary
seekingalpha.com - April 17 at 9:33 AM |
| REGENXBIO (RGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 17 at 8:47 AM |
| Regenxbio Inc (RGNX) SVP Sells $390,000.00 in Stock
www.americanbankingnews.com - April 13 at 7:11 PM |
 | How Analysts Rate Regenxbio and Peers in April 2018
finance.yahoo.com - April 13 at 4:42 PM |
| A Look at Regenxbio’s Recent Financial Performance
finance.yahoo.com - April 13 at 4:42 PM |
| What Investors Should Know about Regenxbio’s Research Pipeline
finance.yahoo.com - April 13 at 4:42 PM |
| How Regenxbio’s Cash Flows and Valuation Metrics Moved
finance.yahoo.com - April 13 at 4:42 PM |
| Chardan Capital Increases Regenxbio (RGNX) Price Target to $55.00
www.americanbankingnews.com - April 11 at 11:23 PM |
| Patrick J. Christmas Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - April 11 at 7:09 PM |
| Regenxbio (RGNX) Given a $45.00 Price Target at Raymond James Financial
www.americanbankingnews.com - April 11 at 6:13 PM |
 | Regenxbio Inc. (RGNX) PT Raised to $29 at Mizuho Securities on $100M Milestone Related to NVX/AVXS
www.streetinsider.com - April 10 at 9:36 AM |
 | How a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech
www.bizjournals.com - April 9 at 4:38 PM |
 | AVXS-101
www.benzinga.com - April 9 at 4:38 PM |
| Regenxbio (RGNX) PT Raised to $90.00
www.americanbankingnews.com - April 9 at 10:28 AM |
| REGENXBIO to receive $180M from NAV AAV9 licensee AveXis on Novartis tie-up; shares ahead 21% premarket
seekingalpha.com - April 9 at 9:25 AM |
| Regenxbio (RGNX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 1:10 PM |
| Regenxbio (RGNX) Price Target Raised to $85.00 at Chardan Capital
www.americanbankingnews.com - March 31 at 7:10 PM |
| Regenxbio (RGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM |
| Regenxbio Inc (RGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 29 at 3:25 AM |
| Regenxbio Inc (RGNX) CFO Sells $150,000.00 in Stock
www.americanbankingnews.com - March 28 at 10:46 PM |
| Insider Selling: Regenxbio Inc (RGNX) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 22 at 7:32 PM |
| Regenxbio (RGNX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 18 at 4:58 PM |
| Edited Transcript of RGNX earnings conference call or presentation 6-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:08 AM |
| Regenxbio (RGNX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 16 at 6:24 AM |
| Insider Selling: Regenxbio Inc (RGNX) SVP Sells 25,000 Shares of Stock
www.americanbankingnews.com - March 15 at 7:46 PM |
| Regenxbio (RGNX) PT Lowered to $35.00 at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:45 AM |
| Regenxbio (RGNX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 10 at 9:54 PM |
| Regenxbio (RGNX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 10 at 2:33 PM |
| Zacks: Brokerages Expect Regenxbio Inc (RGNX) to Announce -$0.69 EPS
www.americanbankingnews.com - March 9 at 5:23 PM |
| Regenxbio (RGNX) Posts Earnings Results, Beats Estimates By $0.28 EPS
www.americanbankingnews.com - March 6 at 7:17 PM |
| Regenxbio Q4 Earnings Outlook
finance.yahoo.com - March 6 at 4:59 PM |
| REGENXBIO, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 4:59 PM |
| Regenxbio Inc (RGNX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 4 at 3:30 AM |
| Regenxbio Inc (RGNX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM |
| Regenxbio Inc (RGNX) Position Lifted by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 1 at 12:04 PM |
| Ascend Capital LLC Sells 180,988 Shares of Regenxbio Inc (RGNX)
www.americanbankingnews.com - March 1 at 4:42 AM |
| REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - February 27 at 5:14 PM |
| Regenxbio (RGNX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM |
| Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - February 22 at 6:46 PM |
| -$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - February 20 at 11:16 PM |
| Mizuho Initiates Coverage on Regenxbio (RGNX)
www.americanbankingnews.com - February 12 at 8:28 PM |
| Regenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis
finance.yahoo.com - February 12 at 4:20 PM |
| BidaskClub Upgrades Regenxbio (RGNX) to Buy
www.americanbankingnews.com - February 10 at 9:24 AM |
| Regenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
www.streetinsider.com - February 9 at 9:23 AM |
| REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
finance.yahoo.com - February 8 at 4:14 PM |
| REGENXBIO to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 8 at 8:46 AM |
| Regenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 7 at 3:24 AM |
REGENXBIO (NASDAQ:RGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
REGENXBIO (NASDAQ:RGNX) Income Statement, Balance Sheet and Cash Flow Statement
REGENXBIO (NASDAQ RGNX) Stock Chart for Monday, April, 23, 2018
Loading chart…
